Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
Amgen
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...
Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development
Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...
Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study
The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...
Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative
Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra,...
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...
Amgen Launches Global Collaboration Network to Advance Oncology Research
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
The National Health Commission (NHC) of China has released an updated national list of rare...
Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial
Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...
Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...
Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition
Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with...
Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...
Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials
US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...